(Stroke. 1999;30:76-80.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Departments of Clinical Neurophysiology (B.M.E., E.B., R.R.B., W.P.) and Psychiatry (G.H.), University of Göttingen, and Department of Neurology, University of Mainz (B.M.E.) (Germany).
Correspondence to B. Martin Eicke, MD, Department of Neurology, Johannes-Gutenberg Universität Mainz, Langenbeckstr 1, D-55101 Mainz, Germany. E-mail eicke{at}neurologie.klinik.uni-mainz.de
| Abstract |
|---|
|
|
|---|
MethodsWe tested vasomotor response in 32 volunteers (age, 42±18 years) with 5% CO2. Acetazolamide (1 g) was tested in 15 volunteers (age, 28±8 years). To evaluate drug-dependent flow changes in the external carotid artery territory, acetazolamide was administered in 7 patients with unilateral occlusion of the internal carotid artery without evidence of collateralization through the ophthalmic artery (age, 67±12 years). Simultaneous recording included measurements of flow volume in the common carotid arteries (M-mode color duplex system) and flow velocity in the middle cerebral arteries.
ResultsWith CO2 and acetazolamide, intracranial flow velocity increased by 31% and 39%, respectively, with a simultaneous increase of common carotid artery flow volume of 47% and 50%, respectively. No change in extracranial flow volume was observed in patients with an occluded internal carotid artery.
ConclusionsThese data show not only the expected increase of flow velocity in the middle cerebral artery but also suggest an increase in cross-sectional vessel diameter of 6% and 4% with CO2 and acetazolamide, respectively. It remains unresolved whether this observation is due to a direct effect of the drug on the vessel walls or is simply pressure dependent.
Key Words: acetazolamide blood flow velocity carbon dioxide cerebral blood flow ultrasonography, Doppler, transcranial vasomotor reactivity
| Introduction |
|---|
|
|
|---|
The introduction of color duplex M-mode systems (Figure 1
) offers the potential to constantly and
noninvasively estimate the carotid flow volume.10 11 12 The
direct comparison of intracranial flow velocity and extracranial flow
volume data may help to differentiate between intracranial flow
velocity increases due to either local vasoconstriction or
hyperperfusion. The goal of this study was the simultaneous
assessment of intracranial blood flow velocity and extracranial blood
flow volume during VMR testing. The question of potential vasodilation
or vasoconstriction due to vasoactive drugs was addressed.
|
| Subjects and Methods |
|---|
|
|
|---|
Extracranially, peak systolic and end-diastolic
flow velocity, peak systolic and end-diastolic
vessel diameter, and flow volume rate in the CCA (raw data) were
measured bilaterally with a specifically developed color duplex M-mode
system (P700 with CVI-Q, Philips Medical Systems). These systems
offer the potential to constantly and noninvasively estimate the
carotid flow volume.10 11 Specifically developed color
M-mode software (CVI-Q), as well as a time-domainbased color duplex
system (with improved temporal and spatial resolution and accuracy of
velocity display), offers easy access to this
hemodynamic parameter.13 These
systems have been tested in vitro and in vivo and have revealed
excellent accuracy, variability, and reliability for the
CCA.11 12 Acceptable insonation of the extracranial
portion of the internal carotid artery (ICA) is possible in only
70% of the vessels, with turbulent flow and lack of sufficient
color filling as limiting factors. Because of unacceptable spatial
resolution with 2-MHz probes, this approach is limited to the
extracranial vessels in adults. The M-mode images were analyzed
peak to peak over a minimum time of 3 seconds and a maximum time of 6
seconds (Figure 1
). Three samples per measurement were taken and
averaged.
Mean temporal velocity and diameter were calculated as
![]() |
|
The end-expiratory CO2 pressure (DatexJ-P) was
registered continuously. Data were transferred on-line and stored on
the hard disk of the DWL system (Figure 2
).
We performed off-line analysis using the event marker of the DWL system, averaging TCD and CO2 data over the time the flow volume data on the duplex system were sampled.
We studied the CO2-dependent VMR in 32 normal, age-matched volunteers (age range, 21 to 82 years; mean age, 42±18 years). Samples were taken with the volunteers breathing normal air and with inhalation of 5% CO2 through a mask (half-open system). Flow volume data were sampled when TCD measurements (flow velocities) showed a plateau phase, usually after 60 to 90 seconds. Hyperventilation for 1 to 2 minutes was performed after a minimum resting time of 5 minutes with the volunteers breathing normal air.
In 15 volunteers (age range, 32 to 74 years; mean age, 28±8 years), we
tested the VMR with acetazolamide. Simultaneous
recordings of intracranial blood flow velocity, extracranial
flow, and CO2 data were sampled at baseline and
after injection of acetazolamide 1 g IV. Maximum MCA flow
velocity data were observed 12 to 20 minutes after injection (Figure 2
).
To study the vasomotor effects of acetazolamide on the territory of the external carotid artery (ECA) exclusively, we additionally studied 7 patients (age range, 62 to 75 years; mean age, 67±12 years) with unilateral ICA occlusion without collateral flow through the ophthalmic artery before and after administration of acetazolamide 1 g IV. These patients were studied only ipsilateral to the side of the occlusion.
The study protocol required written informed consent and was approved by the local ethics committee.
All values are given as mean±SD. Statistical evaluation was performed to compare the induced relative changes of intracranial blood flow velocity and extracranial flow volume with CO2 and acetazolamide. These data were tested for normal distribution (Kolmogoroff-Smirnov test), and the 2-tailed paired t test was applied. Results were considered (locally) significant for P<0.05.
| Results |
|---|
|
|
|---|
Volunteers Tested With CO2
The end-expiratory CO2 content at baseline
was 4.0% and changed to 4.9% with inhalation of a gas mixture with
5% CO2 (Table 1
).
Blood flow velocity in the MCAs increased from baseline values by 19
cm/s (+31%) (Table 2
).
Simultaneously, the flow volume in the CCAs increased by
163 mL/min (+47%) (Table 3
). The
relative increase of extracranial flow volume compared with the
increase of intracranial flow velocity was significantly higher
(P<0.0001) (Figure 3
).
|
|
|
|
The extracranial changes were predominantly but not exclusively due to
increases of blood flow velocity, especially in diastole.
Systolic flow velocity in the CCAs increased by 9 cm/s (+10%)
and diastolic blood flow velocity by 7 cm/s (+42%). The
calculated mean temporal velocity in the CCAs increased by 8 cm/s
(+20%). Systolic vessel diameter in the CCAs increased by
0.3 mm (+4%) and diastolic vessel diameter by
0.4 mm (+7%). Calculated mean temporal diameter in the CCAs
increased by 0.4 mm (+6%) (Table 3
).
Volunteers Tested With Hyperventilation
With hyperventilation, end-expiratory CO2
levels dropped from 4.0% to 2.5% (Table 1
), and intracranial
flow velocity dropped by 18 cm/s (-28%) (Table 2
). Flow
volume dropped simultaneously by 121 mL/min (-35%) (Table 3
). The relative drop of extracranial flow volume compared with
the decrease of intracranial flow velocity was significantly more
pronounced (P<0.05).
The extracranial changes were most obvious in
diastole, with a velocity drop of 6 cm/s (-32%) and a
diameter drop of 0.9 mm (-15%). In systole, a velocity decrease
of 10 cm/s (-12%) and a diameter decrease of 0.4 mm (-5%) were
noted. Calculated mean temporal velocity dropped by 7 cm/s (-17%),
and mean temporal diameter decreased by 0.6 mm (-10%) (Table 3
).
Volunteers Tested With Acetazolamide
The end-expiratory CO2 content at baseline
was 4.4% and changed to 3.9% 15 to 20 minutes after
intravenous injection (Table 1
). Blood flow velocity
in the MCAs increased from baseline values by 6 cm/s (+39%) (Table 2
). Simultaneously, the flow volume in the CCAs
increased by 215 mL/min (+50%) (Table 3
). The relative increase
of CCA flow volume was significantly higher (P<0.005) than
the increase of MCA flow velocity (Figure 3
).
As with CO2, the most decisive factor altering
the extracranial flow volume was the increase of diastolic
flow velocity. Systolic flow velocity in the CCAs increased by
6 cm/s (+6%) and diastolic flow velocity by 9 cm/s
(+43%). Calculated mean temporal velocity in the CCAs increased by 8
cm/s (+16%). Systolic vessel diameter in the CCAs increased by
0.5 mm (+6%) and diastolic vessel diameter by
0.7 mm (+13%). Calculated mean temporal diameter in the CCA
increased by 0.6 mm (+10%) (Table 3
).
Acetazolamide in Patients With Occluded ICA
Despite a moderate increase of blood flow velocity in the
ipsilateral MCA of 13 cm/s (+28%) (Table 2
), no
significant increase in flow volume in the corresponding CCA was
observed (3 mL/min; +2%) (Table 3
) (Figure 3
).
| Discussion |
|---|
|
|
|---|
The VMR can be measured by means of single-photon emission CT (SPECT), with 133Xe8 9 14 15 or hexamethylpropyleneamine oxime (HMPAO)16 17 as tracing substances. A disadvantage of these methods is the requirement of radioactive material and difficulties in monitoring changes over time. Flow velocity of the basal intracranial arteries can be monitored continuously and noninvasively with TCD devices.2 8 9 18 19 20 21 If a constant vessel diameter is assumed, relative flow velocity changes correlate directly with flow volume changes.7
With acetazolamide (1 g IV), maximum flow velocity increases in the MCA of 34% to 60%8 9 15 21 22 23 are observed. Similar results were reported with inhalation of CO2.2 15 19 Comparative rCBF and TCD data are controversial,24 since a slightly less pronounced increase of rCBF compared with intracranial flow velocity was observed. Sorteberg et al8 reported a MCA flow velocity increase with acetazolamide of 36% to 42% versus a rCBF increase of only 24% to 26%; Dahl et al9 found a MCA flow velocity increase of 35% with a corresponding rCBF increase of only 30%. It was assumed that acetazolamide may cause additional vasoconstriction of the major intracerebral vessels. In contrast to the published SPECT data, we noticed not only the anticipated increase of flow velocity in the MCA but also an even more pronounced flow volume increase in the extracranial brain-supplying arteries, predominantly in diastole.
It was possible to exclude that the flow volume changes in the CCA were due to increased perfusion in the ECA territory. For this reason, patients with unilateral occlusion of the ICA who had no evidence of collateral flow through the ophthalmic arteries were studied. Flow volume in these patients did not change after injection of acetazolamide. These results are in contrast to published data by Demolis et al,25 who showed a moderate increase of blood flow of 34% in the ECA territory induced by acetazolamide as measured by cutaneous facial blood flow.
A potential explanation for the contradictory results of the aforementioned rCBF studies and our findings is the absolute simultaneous assessment of blood flow velocity and flow volume in our study. SPECT data are based on one-time measurements, and the time course of vasomotor responses may differ.22 It appears possible that the documented rCBF data did not represent the highest flow increase. Continuous TCD monitoring allows exact determination of the maximum flow velocity. Possibly the maximum increase of flow velocity was compared with a submaximal increase of rCBF. Another explanation is a possible underestimation of rCBF by SPECT due to low first-pass extraction in high blood flow regions.26
The discrepancy between extracranial flow volume and intracranial flow
velocity data indicates a minor to moderate increase in cross-sectional
intracranial vessel diameter and area. This area increase can be
estimated as follows:
![]() |
![]() |
It remains unresolved whether the reported observation is due to a direct effect of the drug on the vessel walls or is strictly pressure dependent. The relative increase of vessel diameter in CCA and MCA appears to be similar.
No major clinical consequences arose from these results. It could be demonstrated that relative intracranial flow velocity changes are within acceptably close limits compared with changes of flow volume. Testing of VMR with TCD is easy to perform and correlates directly with the volumetric changes in the brain-supplying arteries.
One future application of simultaneous assessment of extracranial flow volume and intracranial flow velocity will be in patients with subarachnoid hemorrhage. High flow velocities, as shown by TCD, were interpreted in the past as functional stenoses due to vasospasm28 29 and consecutive hypovolemic flow. Recently it has been hypothesized that some of these flow velocity increases may instead be due to physiological hypervolemic flow or luxury perfusion.30 31 Simultaneous assessment of flow volume and flow velocity according to the protocol of this study may help to solve this diagnostic problem noninvasively.
Received August 13, 1998; revision received October 13, 1998; accepted October 13, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. S. Y. Ho, W. W-m. Lam, S. C. P. Ng, M. K. Lam, M. T. V. Chan, W. S. Poon, and C. Metreweli Cerebral Vasoreactivity: A Comparison of Color Velocity Imaging Quantification and Stable Xenon-Enhanced CT Am. J. Roentgenol., March 1, 2005; 184(3): 948 - 952. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-D. Niesen, M. Rosenkranz, B. Eckert, M. Meissner, C. Weiller, and U. Sliwka Hemodynamic Changes of the Cerebral Circulation after Stent-Protected Carotid Angioplasty AJNR Am. J. Neuroradiol., August 1, 2004; 25(7): 1162 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Gundamraj and K. K. Lauer Diagnosis of Intracranial Arterial Stenosis Using Transcranial Doppler Flowmetry Anesth. Analg., June 1, 2004; 98(6): 1776 - 1778. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. de Boorder, J. Hendrikse, and J. van der Grond Phase-Contrast Magnetic Resonance Imaging Measurements of Cerebral Autoregulation With a Breath-Hold Challenge: A Feasibility Study Stroke, June 1, 2004; 35(6): 1350 - 1354. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Schreiber, S. Gottschalk, M. Weih, A. Villringer, and J. M. Valdueza Assessment of Blood Flow Velocity and Diameter of the Middle Cerebral Artery during the Acetazolamide Provocation Test by Use of Transcranial Doppler Sonography and MR Imaging AJNR Am. J. Neuroradiol., July 1, 2000; 21(7): 1207 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Y. Ho and C. Metreweli Preferred Technique for Blood Flow Volume Measurement in Cerebrovascular Disease Stroke, June 1, 2000; 31(6): 1342 - 1345. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |